46th Annual ICAAC Interscience Conference on Antimicrobial Agents and Chemotherapy

Conference Reports for NATAP


46th Annual ICAAC Interscience Conference on Antimicrobial Agents and Chemotherapy Sept 27-30, 2006, San Francosco

	The PRESCO study: role of extended therapy and/or optimal doses of ribavirin in the treatment of chronic hepatitis C in HIV-infected patients (12/12/06) Analysis of CCR5 Binding Kinetics and Coupling States Reveals Distinctive Binding Properties of Small Molecule CCR5 Antagonists (10/31/06) Resistance Before Therapy, Hidden Mutations, and Blips - Written for NATAP by Mark Mascolini - (10/24/06) Adherence Slips & Viral Blips - Written for NATAP by Mark Mascolini - (10/24/06) Resistance analysis of TDF/FTC-versus-AZT/3TC trial - Written for NATAP by Mark Mascolini - (10/24/06) Standard Genotyping Does Not Pick Up All Resistance - Written for NATAP by Mark Mascolini - (10/24/06) Resistance to Tipranavir & other PIs - Written for NATAP by Mark Mascolini - (10/24/06) U.S. Resistance & NNRTI Rates Still Rising in Untreated - Written for NATAP by Mark Mascolini - (10/24/06) Tenofovir and Lopinavir Levels in Pregnant Women and Infants - Written for NATAP by Mark Mascolini - (10/16/06) Complications of Three Simplifying Strategies - Written for NATAP by Mark Mascolini - (10/16/06) Cell Studies Predict Cross-Resistance Among Integrase Inhibitors - Written for NATAP by Mark Mascolini -- (10/16/06) Age, Depression, and CD4 Gains - Written for NATAP by Mark Mascolini - (10/16/06) HIV Antiretroviral-Related Hyperlipidemia is Mitigated by HCV Co-Infection - (10/16/06) Distribution Of Susceptibility Among HIV-1 Clinical Samples Submitted For Enfuvirtide (ENF) Resistance Testing - (10/16/06) Baseline viral load (400,000 IU/mL) as a predictor of SVR rate with peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) in HCV/HIV Coinfected in Apricot Study - (10/16/06) Needle-free administration (Biojector) of enfuvirtide significantly reduces incidence of painful injection site reactions: results from a single blind, randomized, controlled study - (10/16/06) Increased Risk of Clinical Event if CD4 <200 After Starting HAART - (10/16/06) Defining Lower (L) and Upper (U) Phenotypic Clinical Cutoffs (CCO's) for Tipranavir/r (TPV), Lopinavir/r (LPV), Saquinavir (SQV) and Amprenavir (APV) Co-Administered with Ritonavir (r) Within the RESIST Dataset by the PhenoSense Assay - (10/16/06) Atazanavir/ritonavir (ATV/RTV) and Efavirenz (EFV) NRTI-Sparing Regimens in Treatment-Naive Adults - (10/16/06) Abacavir Once Daily Had Fewer HSR than Twice Daily (ALOHA Study) - (10/06/06) Needle-free administration (Biojector) of enfuvirtide significantly reduces incidence of painful injection site reactions: results from a single blind, randomized, controlled study - (10/06/06) Good News and Mixed News on New Antiretrovirals: Integrase and CCR5 Inhibitors, a Nuke, and a Nonnuke - Written for NATAP by Mark Mascolini - (10/05/06) Affect of R5 & X4/R5 Tropism on CD4 Count, HIV-RNA, and Response to HAART - (10/05/06) Clinical course of increased LFTs and hepatic events associated with ritonavir (RTV)-boosted tipranavir (TPV/r) based therapy in the RESIST trials - (10/04/06) Impact of protease mutations L33 F/I, V82A, I84V, and L90M on ritonavir-boosted protease inhibitor susceptibility - (10/04/06) Incidence of Drug Resistance Mutations in ART Naives from 2000 to 2005 in USA - (10/04/06) New CCR5 Drug HGS004 Study Results - (10/04/06) New CCR5 Drug HGS004 Phase 1 Study Results - (10/04/06) Lower Reported Rate of Suspected Hypersensitivity Reactions (HSR) to Abacavir (ABC) Among Black Patients - (10/03/06) TMC114 Susceptibility Against 56,000 Patient Samples - (10/03/06) Contamination of Environmental Surfaces During Normal Daily Activities of Hotel Guests with Rhinovirus Colds - (10/03/06) Can Razor Blades Transmit Hepatitis B? - (10/02/06) Safety, Tolerability & Efficacy of Abacavir/Lamivudine/Zidovudine vs. Atazanavir & Lamivudine/Zidovudine in Antiretroviral Naive Subjects - (10/02/06) Potent Antiretroviral Effect of MK-0518, a Novel HIV-1 Integrase Inhibitor, in Patients with Triple-class Resistant Virus: 24 Week Data - (10/02/06) Darunavir Equally Effective After LPV, FPV, or TPV Failure - Written for NATAP by Mark Mascolini - (10/02/06) Efavirenz/Tenofovir Fails as 2-Drug Maintenance Regimen - Written for NATAP by Mark Mascolini - (10/02/06) Integrase Inhibitor Shows Strength in Treatment Experienced - Written for NATAP by Mark Mascolini- (10/02/06) CD4s Plateau at Lower Level When Treatment Starts Late - Written for NATAP by Mark Mascolini - (10/02/06) Fosamprenavir/RTV 1400/100 Once Daily vs Reyataz/RTV Once Daily - (10/02/06) HCV-796 Displays Potent Antiviral Activity in Replicon and in Chimeric Mice Infected with Hepatitis C Virus (HCV) - (10/02/06) Efficacy and Novel Pharmacology of Elvucitabine in a 7 Day Placebo Controlled Monotherapy Study - (10/02/06) The Nucleoside Inhibitor MK-0608 Mediates Suppression of HCV Replication for >30 Days in Chronically Infected Chimpanzees - (10/02/06) Roche HCV Polymerase Inhibitor: two preclinical studies - (10/02/06) Week 24 Results and Baseline Phenotypic Susceptibility in Treatment Experienced Patients Initiating the Combination of TMC114/r and TMC 125 - (09/29/06) "Hidden" Mutations Contribute to Failure of Trizivir/Tenofovir - Written for NATAP by Mark Mascolini - (09/29/06) Another Look at Three Nukes (Trizivir)--Versus Unboosted Atazanavir - Written for NATAP by Mark Mascolini - (09/29/06) Slips in Adherence Tied to Transient Viremia ("Blips") - Written for NATAP by Mark Mascolini - (09/29/06) Nucleoside-Sparing Regimen Coupling Atazanavir/Ritonavir and Efavirenz - Written for NATAP by Mark Mascolini - (09/29/06) Critical Interactions Between Darunavir (TMC114), Lopinavir, Viagra, and Oral Contraceptives - Written for NATAP by Mark Mascolini - (09/28/06) HIV May Like Different Coreceptors in Blood and Brain - Written for NATAP by Mark Mascolini - (09/28/06) PL-100, a Next Generation Protease Inhibitor Against Drug-Resistant HIV: In vitro & IN Vivo Metabolism - (09/28/06) Cell Studies Predict Cross-Resistance Among Integrase Inhibitors - Written for NATAP by Mark Mascolini - (09/28/06) Integrase Inhibitor Has Little 24-Week Impact on Lipids - Written for NATAP by Mark Mascolini - (09/28/06) Integrase MK-0518 Does Not Increase Lipids After 24 Weeks in Naives - (09/28/06)